Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Sanofi, the French pharmaceutical company, will be helping Moderna with the production of COVID-19 vaccines. The move was made in an effort to allow the American pharmaceutical and biotechnology firm to fulfill its orders and meet the demand for its shots.
Sanofi confirms production of Moderna shots
On Monday, April 26, Sanofi said that it has joined hands with the Massachusetts-headquartered biotech firm so it can provide assistance with filling vials and finish the packaging of up to 200 million doses as the demand for the Moderna COVID-19 vaccine is high.
Sanofi will be manufacturing the shots in its facility in Ridgefield, New Jersey. While the French company shared some info about its latest partnership with Moderna, it did not disclose any detail regarding the financial aspect of their deal, as per CNBC.
This is the third contract that Sanofi was able to secure since the start of this year. It previously signed a deal with Pfizer/BioNTech, to help them with supplying more than 125 million doses of coronavirus shots. The company also pledged to complete the filling and packing of Johnson & Johnson vaccines, and it must churn out at least 12 million doses per month.
Sanofi’s contribution in fulfilling Moderna’s COVID-19 vaccine supply will begin in September. While it has many deals to work on, the company is also busy in the development of its own vaccines in partnership with GlaxoSmithKline and another one with Translate Bio.
Sanofi aims to fill the bill for vaccines in the U.S.
The Wall Street Journal reported that based on the info coming from Sanofi’s spokesman, the finished doses of Moderna vaccines are for the U.S. supply where Moderna has an agreement until April 2022.
Meanwhile, Novartis AG and Merck Co. are also helping other makers of the coronavirus vaccines by forming agreements for production. The collaborations among the manufacturers are a collective effort to increase production so every nation in the world can have the doses they need.
Finally, Moderna is planning to distribute a total of 300 million doses of COVID-19 shots in the U.S. by the end of July. The delivery is projected to help President Biden achieve his goal of having the majority of American adults vaccinated by summer.
